Outcomes of serial MRI/ultrasound fusion targeted biopsy in men with very low-risk and low-risk prostate cancer managed with active surveillance.
Hsiang W, Ghabili K, Syed J, Nguyen K, Suarez-Sarmiento A, Leapman M, Sprenkle P. Outcomes of serial MRI/ultrasound fusion targeted biopsy in men with very low-risk and low-risk prostate cancer managed with active surveillance. Journal Of Clinical Oncology 2018, 36: 114-114. DOI: 10.1200/jco.2018.36.6_suppl.114.Peer-Reviewed Original ResearchMRI/US fusion biopsyLow-risk prostate cancerNational Comprehensive Cancer NetworkFusion biopsyActive surveillanceSystematic biopsyProstate cancerGleason upgradeMagnetic resonance imagingPSA densitySubsequent biopsyFavorable-risk prostate cancerMRI/ultrasound fusionSerial magnetic resonance imagingProportion of patientsRisk prostate cancerComprehensive Cancer NetworkLow-risk criteriaRisk of reclassificationLogistic regression modelsBiopsy upgradeMedian PSAGleason scoreHigher PSAInstitutional databaseComparison of a low-cost immunohistochemistry marker panel with a cell-cycle progression assay for the prediction of outcome after radical prostatectomy.
Leapman M, Nguyen H, Cowan J, Xue L, Stohr B, Simko J, Cooperberg M, Carroll P. Comparison of a low-cost immunohistochemistry marker panel with a cell-cycle progression assay for the prediction of outcome after radical prostatectomy. Journal Of Clinical Oncology 2018, 36: 118-118. DOI: 10.1200/jco.2018.36.6_suppl.118.Peer-Reviewed Original ResearchPCa-specific mortalityRadical prostatectomyBiochemical recurrenceCCP scoreIHC panelCell cycle progression scoreExpression statusERG expressionCox proportional hazards regressionRisk of BCRPositive ERG expressionProportional hazards regressionProstate cancer riskPrediction of outcomeHigh Ki67Median ageIndependent predictorsPathologic characteristicsHazards regressionPrognostic utilityIHC statusInstitutional databaseLocalized PCaC-indexImmunohistochemistry panel